Loading…
FUCIDIN H is a brand name for Hydrocortisone. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Fucidin H cream is indicated in eczema and dermatitis with secondary bacterial infections, including atopic eczema, primary irritant dermatitis and allergic and seborrhoeic dermatitis where the organisms responsible are known to be or believed to be sensitive to fusidic acid.
Verbatim from this product's MHRA label. Tap a section to expand.
Adults and Children:
Uncovered lesions - a small quantity should be applied to the affected area twice daily until a satisfactory response is obtained. A single treatment course should not normally exceed 2 weeks. Covered lesions - less frequent applications may be adequate.
The estimation of the frequency of adverse reactions is based on a pooled analysis of data from clinical studies and spontaneous reporting. The most frequently reported adverse reactions during treatment are application site reactions including pruritus, burning and irritation.
Adverse reactions are listed by MedDRA system organ class (SOC) and the individual adverse reactions are listed starting with the most frequently reported. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Very common > 1/10 Common > 1/100 and < 1/10 Uncommon > 1/1,000 and < 1/100 Rare > 1/10,000 and < 1/1,000 Very rare < 1/10,000 Not known (cannot be estimated from the available data) Immune system disorders Uncommon (≥1/1,000 and <1/100) Hypersensitivity Eye disorders Not known Vision, blurred* Skin and subcutaneous tissue disorders Uncommon: (≥1/1,000 and <1/100) Dermatitis contact Eczema (condition aggravated) Rash Not known Withdrawal reactions - redness of the skin which may extend to areas beyond the initial affected area, burning or stinging sensation, itch, skin peeling, oozing pustules* General disorders and administration site conditions Common: (≥1/1,00 and <1/10) Application site reaction (incl.
4). 4). Dermatological undesirable class effects of mild corticosteroids like hydrocortisone include: Atrophy, dermatitis (incl. dermatitis contact, dermatitis acneiform and perioral dermatitis), skin striae, telangiectasia, rosacea, erythema, depigmentation, hypertrichosis and hyperhidrosis.
Ecchymosis may also occur with prolonged use of topical corticosteroids. 4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Long-term continuous topical therapy with Fucidin H cream should be avoided. Depending on the application site, possible systemic absorption of hydrocortisone acetate should always be considered during treatment with Fucidin H cream.
Due to the content of corticosteroid, Fucidin H cream should be used with care near the eyes. 8). Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur with or without occlusions following systemic absorption of topical corticosteroids. 8). Bacterial resistance has been reported to occur with the topical use of fusidic acid.
As with all antibiotics, extended or recurrent use of fusidic acid may increase the risk of developing antibiotic resistance. Limiting therapy with topical fusidic acid and hydrocortisone acetate to no more than 14 days at a time will minimise the risk of developing resistance.
This also prevents the risk that the immunosuppressive action of corticosteroid might mask any potential symptoms of infections due to antibiotic-resistant bacteria. Steroid antibiotic combinations should not be continued for more than 7 days in the absence of any clinical improvement.
Due to the immunosuppressant effect of corticosteroids, Fucidin H cream may be associated with increased susceptibility to infection, aggravation of existing infection, and activation of latent infection. 3). As Fucidin H cream contains a corticosteroid it is not recommended in the following conditions: atrophic skin, cutaneous ulcer, acne vulgaris, fragile skin veins and perianal and genital pruritus.
1. 4). Skin manifestations in relation to tuberculosis, either untreated or uncontrolled by appropriate therapy. Perioral dermatitis and rosacea.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Hydrocortisone in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Contact with open wounds and mucous membranes should be avoided. As with all corticosteroids, prolonged use on the face should be avoided. Fucidin H cream contains butyl hydroxyanisole, cetyl alcohol and potassium sorbate. g. contact dermatitis).
Butyl hydroxyanisole may also cause irritation to the eyes and mucous membranes. Fucidin H cream contains polysorbate 60. Polysorbates can cause allergic reactions. Instruct patients not to smoke or go near naked flames – risk of severe burns.
Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it. Long term use of topical steroids can result in the development of rebound flares after stopping treatment (topical steroid withdrawal syndrome).
A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and burning that can spread beyond the initial treatment area. It is more likely to occur when delicate skin sites such as the face and flexures are treated.
Should there be a reoccurrence of the condition within days to weeks after successful treatment a withdrawal reaction should be suspected. Reapplication should be with caution and specialist advise is recommended in these cases or other treatment options should be considered.
The label will state mild steroid.